

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## RPP decision paper

**Review of TA279; Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures**

### **Final recommendation post consultation**

The guidance should be transferred to the 'static guidance' list.

#### **1. Background**

This guidance was issued in April 2013.

At the GE meeting of 10 November 2015 it was agreed that we would consult on the recommendations made in the GE proposal paper. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

#### **2. Proposal put to consultees and commentators**

The guidance should be transferred to the 'static guidance' list.

#### **3. Rationale for selecting this proposal**

The systematic review suggests that the new evidence identified is broadly consistent with the Committee's considerations in Technology Appraisal 279 (TA279). In particular, no evidence was identified to suggest that vertebroplasty and balloon kyphoplasty are substantially less effective than previously thought, and limited evidence was found to address key uncertainties about the survival benefits associated with these treatments.

#### **4. Summary of consultee and commentator responses**

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

<p><b>Respondent:</b> Johnson &amp; Johnson Medical</p> <p><b>Response to proposal:</b> Agree</p> <p>Johnson &amp; Johnson Medical concur with this decision.</p>	<p><b>Comment from Technology Appraisals</b></p> <p>Thank you for your comment. No changes to the recommendation are needed.</p>
<p><b>Respondent:</b> Medtronic</p> <p><b>Response to proposal:</b> Agree</p> <p>The Institutes review of the studies, and conclusion that they are broadly consistent with the committee’s conclusions in TA279, is in line with our own supporting evidence provided as part of the review planning. Consequently Medtronic support the Guidance Executive’s proposal to place TA279 on to the static list.</p>	<p><b>Comment from Technology Appraisals</b></p> <p>Thank you for your comment. No changes to the recommendation are needed.</p>
<p><b>Respondent:</b> Royal College of Nursing</p> <p><b>Response to proposal:</b> Agree</p> <p>Nurses caring for people with osteoporotic fractures were invited to review the documents on behalf of the RCN.</p> <p>Our members have indicated that they not aware of any other groups that should be involved in this consultation in addition to the ones listed by NICE. They have also commented that they are not aware of any evidence that would influence the decision to change existing recommendations.</p>	<p><b>Comment from Technology Appraisals</b></p> <p>Thank you for your comment. No changes to the recommendation are needed.</p>

**Paper signed off by:** Elisabeth George, 21 December 2015

**Contributors to this paper:**

Technical Lead: Ian Watson

Project Manager: Andrew Kenyon